Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPL554 (Ensifentrine) with Tiotropium/Olodaterol in COPD
NCT03673670Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Jul 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ensifentrine in chronic obstructive pulmonary disease (COPD), sponsored by Verona Pharma. Started Jul 2018; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03673670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673670.